Ginkgo Bioworks DNA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -210.7%-18.7pp | -192%+7.5pp | -199.5%-61.1pp | -138.3%+65.2pp | -203.5%+43.0pp | |
| Net margin | -215.4%-20.0pp | -195.4%+3.7pp | -199.1%-56.3pp | -142.8%+64.9pp | -207.7%+33.3pp | |
| Returns | ||||||
| Return on equity | -55.8%-4.7pp | -51.1%-1.1pp | -50%-6.4pp | -43.6%+14.2pp | -57.8%+2.6pp | |
| Return on invested capital | -42.8%+4.0pp | -46.8%+1.6pp | -48.3%+8.7pp | -57%+30.2pp | -87.2%+33.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.2×+0.2× | 4.9×+0.5× | 4.4×-1.0× | 5.4×+0.5× | 4.9×-0.7× | |
| Leverage | ||||||
| Debt-to-equity | 0.9×+0.1× | 0.9×+0.1× | 0.8×+0.1× | 0.7×0.0× | 0.7×0.0× | |
| Valuation | ||||||
| Market capitalization | $625.16M+24.6% | $503.5M-41.7% | $863.13M+60.5% | $537.91M+62.6% | $330.79M-41.4% | |
| Price / sales | 4.4×+2.2× | 3.1×-1.9× | 5.1×+2.6× | 2.4×+1.0× | 1.5×-1.0× | |
| Price / book | 1.4×+0.6× | 1×-0.6× | 1.5×+0.7× | 0.9×+0.4× | 0.5×-0.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Ginkgo Bioworks's ratios come from?
- Every ratio is computed from Ginkgo Bioworks's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
